MedPath

The effects of Warfarin on permacath functio

Phase 2
Conditions
Chronic kidney disease.
Chronic kidney disease (CKD)
Registration Number
IRCT20200516047461N1
Lead Sponsor
Esfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
86
Inclusion Criteria

Patients who were a candidate for the second time embedding of permanent arteriovenous catheters
Informed consent to participate in the study
Age above 18 years old

Exclusion Criteria

History of major hemorrhages (requiring blood transfusion, retroperitoneal or intracranial hemorrhage, inducing hypovolemia, leading to more than two units decrease in hemoglobin) within the previous three months
Progressive diabetic retinopathy
Less than 12 months of life-expectancy because of systemic disease or malignancies
Poorly controlled hypertension (systolic blood pressure>200 mmHg or diastolic blood pressure>100 mmHg measured three times within two weeks)
Absolute platelet count less than 100000
International normalized ratio (INR)=1.3
Partial thrombin time (PTT)= 5 folds than the normal range
Hypersensitivity to Warfarin
Active peptic ulcer
Pregnancy or lactation
Documented aortic aneurysm

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Permcath function. Timepoint: In every hemodialysis session. Method of measurement: Catheter clotting defined as the gross visible occlusion of the catheter or the dialysis performance with less than 250 ml per minute velocity.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath